Millipore Corporation (NYSE:MIL), a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.
“ProRes-S media brings the biomanufacturing industry increased efficiencies to their purification process.”
"Combining Millipore's expertise in purification with Dow's extensive experience in ion-exchange resins technology allows us to offer biopharmaceutical manufacturers a substantially expanded chromatography solution," said Paul Chapman, Vice President of Millipore's Downstream Processing Business Unit. "ProRes-S media brings the biomanufacturing industry increased efficiencies to their purification process."
ProRes-S media, a semirigid cation exchange resin, offers a broader operating window over a wider range of conductivities, is optimized for resolving difficult impurities and allows higher bed packing.
Antibody engineering drives innovation in drug development